PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-1070

  1. 92 Posts.
    lightbulb Created with Sketch. 10
    It was interesting to go back and read the early 51 Capital reports. They were talking about the possibility of not even needing a Phase 3 trial. Back then you would assume that by Jan 2021 we'd be sitting on share price > $10. Let's hope the TGA will be kinder to us than FDA have been so far!
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.